The Renaissance of Cancer Immunotherapy
The journal Science named cancer immunotherapy as “the breakthrough of the year”; but challenges still remain to overcome tumor immune suppression and genomic instability.
The journal Science named cancer immunotherapy as “the breakthrough of the year”; but challenges still remain to overcome tumor immune suppression and genomic instability.
Patients with glioblastoma have very few treatment options to prolong survival; however, a new vaccine may change that.
Researchers have discovered a novel approach to making ovarian tumor cells more visible to anticancer therapy.
Cell-based immunotherapy may offer new therapy options for patients with metastatic RCC.
As the need for access to live tumor cells grows, patients turn to companies that store tumors for testing and research.
Cancer immunoediting of a mutation expressed in highly immunogenic sarcomas derived from immunodeficient mice occurs via a T-cell-dependent process.